"Aspirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
| Descriptor ID |
D001241
|
| MeSH Number(s) |
D02.455.426.559.389.657.410.595.176
|
| Concept/Terms |
Aspirin- Aspirin
- Acetylsalicylic Acid
- Acid, Acetylsalicylic
- 2-(Acetyloxy)benzoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Aspirin".
Below are MeSH descriptors whose meaning is more specific than "Aspirin".
This graph shows the total number of publications written about "Aspirin" by people in this website by year, and whether "Aspirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 2 | 4 |
| 1997 | 4 | 2 | 6 |
| 1999 | 2 | 1 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 1 | 5 |
| 2003 | 5 | 5 | 10 |
| 2004 | 3 | 7 | 10 |
| 2005 | 4 | 1 | 5 |
| 2006 | 10 | 3 | 13 |
| 2007 | 5 | 7 | 12 |
| 2008 | 4 | 11 | 15 |
| 2009 | 3 | 11 | 14 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 3 | 7 |
| 2013 | 3 | 4 | 7 |
| 2014 | 2 | 5 | 7 |
| 2015 | 4 | 1 | 5 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 3 | 6 |
| 2018 | 5 | 2 | 7 |
| 2019 | 11 | 2 | 13 |
| 2020 | 6 | 4 | 10 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 7 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspirin" by people in Profiles.
-
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 02; 8(8):777-785.
-
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023 Feb; 151(2):386-398.
-
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 01; 370:51-57.
-
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. J Neurol Sci. 2022 10 15; 441:120334.
-
Should Patients Take Aspirin for Primary Cardiovascular Prevention?: Updated Recommendations From the US Preventive Services Task Force. JAMA. 2022 04 26; 327(16):1552-1554.
-
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 03 22; 98(12):486-498.
-
Staging Endovascular Thoracic and Thoracoabdominal Aortic Aneurysm Repairs and the Risk of Post-operative Spinal Cord Ischemia. Ann Vasc Surg. 2022 Sep; 85:299-304.
-
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2022 04; 21(4):355-368.
-
Evaluation of aspirin platelet inhibition in left ventricular assist device population. J Card Surg. 2021 Dec; 36(12):4503-4508.
-
Identification of a potent Nrf2 displacement activator among aspirin-containing prodrugs. Neurochem Int. 2021 10; 149:105148.